P
10.17
-1.08 (-9.60%)
| Previous Close | 11.25 |
| Open | 11.20 |
| Volume | 1,557,933 |
| Avg. Volume (3M) | 1,517,685 |
| Market Cap | 903,140,288 |
| Price / Sales | 11.41 |
| Price / Book | 4.84 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | -98.10% |
| Operating Margin (TTM) | -85.88% |
| Diluted EPS (TTM) | -1.29 |
| Quarterly Revenue Growth (YOY) | 5.50% |
| Total Debt/Equity (MRQ) | 21.81% |
| Current Ratio (MRQ) | 6.91 |
| Operating Cash Flow (TTM) | -42.70 M |
| Levered Free Cash Flow (TTM) | -23.09 M |
| Return on Assets (TTM) | -17.90% |
| Return on Equity (TTM) | -51.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Bullish |
| Diagnostics & Research (Global) | Bullish | Bullish | |
| Stock | Personalis, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.5
| Analyst Consensus | 1.5 |
| Insider Activity | -1.5 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.50 |
|
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 31.49% |
| % Held by Institutions | 46.11% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 13.00 (Guggenheim, 27.83%) | Buy |
| 13.00 (HC Wainwright & Co., 27.83%) | Buy | |
| Median | 12.50 (22.91%) | |
| Low | 11.00 (Morgan Stanley, 8.16%) | Hold |
| Average | 12.25 (20.45%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 9.25 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 26 Jan 2026 | 13.00 (27.83%) | Buy | 10.36 |
| 11 Nov 2025 | 12.00 (17.99%) | Buy | 8.44 | |
| BTIG | 09 Jan 2026 | 12.00 (17.99%) | Buy | 8.10 |
| 11 Nov 2025 | 12.00 (17.99%) | Buy | 8.44 | |
| Morgan Stanley | 02 Dec 2025 | 11.00 (8.16%) | Hold | 10.10 |
| 11 Nov 2025 | 9.00 (-11.50%) | Hold | 8.44 | |
| HC Wainwright & Co. | 11 Nov 2025 | 13.00 (27.83%) | Buy | 8.44 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |